Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Antiretroviral resistance during successful therapy of HIV type 1 infection.

Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, Rosenberg E, Gunthard HF, Sutton L, Savara A, Petropoulos CJ, Hellmann N, Walker BD, Richman DD, Siliciano R, D'Aquila RT.

Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10948-53.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.
4.

Antiretroviral therapy. Sequencing antiretrovirals.

MacArthur RD.

AIDS Read. 2000 Jun;10(6):359-64. Review.

PMID:
10881367
5.

Resistance against reverse transcriptase inhibitors.

O'Brien WA.

Clin Infect Dis. 2000 Jun;30 Suppl 2:S185-92. Review.

PMID:
10860904
6.

HIV mutagenesis and the evolution of antiretroviral drug resistance.

Mansky LM.

Drug Resist Updat. 2002 Dec;5(6):219-23. Review.

PMID:
12531178
7.

Preventing HIV antiretroviral resistance through better monitoring of treatment adherence.

Bangsberg DR.

J Infect Dis. 2008 May 15;197 Suppl 3:S272-8. doi: 10.1086/533415. Review.

PMID:
18447613
8.

Current progress in the development of RNAi-based therapeutics for HIV-1.

Zhou J, Rossi JJ.

Gene Ther. 2011 Dec;18(12):1134-8. doi: 10.1038/gt.2011.149. Epub 2011 Sep 29. Review.

9.

Current concepts in human immunodeficiency virus infection and AIDS.

Schwartz SA, Nair MP.

Clin Diagn Lab Immunol. 1999 May;6(3):295-305. Review. No abstract available.

10.

Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Vandamme AM, Van Laethem K, De Clercq E.

Drugs. 1999 Mar;57(3):337-61. Review.

PMID:
10193687
11.

Ubiquitin ligases as therapeutic targets in HIV-1 infection.

Votteler J, Schubert U.

Expert Opin Ther Targets. 2008 Feb;12(2):131-43. doi: 10.1517/14728222.12.2.131 . Review.

PMID:
18208363

Supplemental Content

Support Center